PulmCrit – High-dose anakinra for COVID-19: The anti-inflammatory trials begin
A randomized controlled pilot trial of anakinra for hemodialysis inflammation - Kidney International
Cancers | Free Full-Text | Immune Effector Cell-Associated HLH-like Syndrome: A Review of the Literature of an Increasingly Recognized Entity
Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome - The Lancet Rheumatology
Current evidence on the use of anakinra in COVID-19 - ScienceDirect
The use of anakinra in the treatment of secondary hemophagocytic lymphohistiocytosis - Bami - 2020 - Pediatric Blood & Cancer - Wiley Online Library
Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy - Transplantation and Cellular Therapy, Official Publication of the American Society for ...
CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results | Nature Medicine
Development and effect of antibodies to anakinra during treatment of severe CAPS: sub-analysis of a long-term safety and efficacy study | Clinical Rheumatology
Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy - Transplantation and Cellular Therapy, Official Publication of the American Society for ...
Higher-dose Anakinra Is Effective in a Case of Medically Refractory Macrophage Activation Syndrome | The Journal of Rheumatology
JCM | Free Full-Text | Anakinra versus Baricitinib: Different Strategies for Patients Hospitalized with COVID-19
KINERET® (anakinra) Official Website | Using KINERET for NOMID
Clinical Commissioning Policy: Anakinra for Haemophagocytic Lymphohistiocytosis (HLH) for adults and children in all ages [21070
Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS) | Journal for ImmunoTherapy of Cancer
2019 Clinical Guidelines Template
IJMS | Free Full-Text | Towards a Treatment for Neuroinflammation in Epilepsy: Interleukin-1 Receptor Antagonist, Anakinra, as a Potential Treatment in Intractable Epilepsy
Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes | BMC Pharmacology and Toxicology | Full Text
Arthritis News: Study Finds No Treatment Benefit of Intra-Articular Anakinra in Knee Osteoarthritis
Frontiers | Anakinra in Paediatric Rheumatology and Periodic Fever Clinics: Is the Higher Dose Safe?
Kineret, INN-anakinra
Anakinra in Patients With Systemic Juvenile Idiopathic Arthritis: Long-term Safety From the Pharmachild Registry | The Journal of Rheumatology
KINERET® (anakinra) Official HCP Website | Dosing Calculator
